Markets:

Overview

News

Currencies

International

Treasuries

Daiichi Sankyo S/Adr (OP:DSNKY)

19.05 -0.27 (-1.37%)

Streaming Delayed Price Updated: 10:02 AM EST, Feb 18, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Daiichi Sankyo S/Adr

< Previous 1 2 3 Next >

Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally

November 07, 2025

The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗

June 24, 2025

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due.

Via Benzinga

AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗

April 21, 2025

AstraZeneca's Enhertu combo improved progression-free survival in HER2+ metastatic breast cancer in a Phase 3 trial, showing promising early results.

Via Benzinga

DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024 ↗

August 13, 2024

Daiichi Sankyo Co just reported results for the first quarter of 2024.

Via InvestorPlace

Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact ↗

March 20, 2023

Via Benzinga

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗

March 21, 2025

UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness.

Via Benzinga

FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗

January 28, 2025

FDA approves Enhertu for metastatic breast cancer with HER2-low or HER2-ultralow expression after showing significant efficacy in the DESTINY-Breast06 trial.

Via Benzinga

FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗

January 21, 2025

AstraZeneca's Datroway gains FDA approval for HR-positive, HER2-negative breast cancer after prior therapies, based on Phase 3 trial data.

Via Benzinga

After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗

December 06, 2024

AstraZeneca's Imfinzi gains FDA Priority Review for bladder cancer. Key trial data shows improved survival and progression outcomes in treated patients.

Via Benzinga

Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗

September 23, 2024

AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free...

Via Benzinga

Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗

September 17, 2024

Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival...

Via Benzinga

AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗

September 10, 2024

AstraZeneca shared detailed results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan for non-small cell lung cancer, showing a clinically meaningful trend in overall survival compared to...

Via Benzinga

Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗

August 07, 2024

"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say.

Via Benzinga

Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗

July 30, 2024

Merck reports Q2 sales of $16.1 billion, a 7% increase YoY, beating estimates. Keytruda sales surged 16% to $7.27 billion. FDA approvals for Capvaxive and Winrevair highlight the quarter. Merck revises...

Via Benzinga

The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 ↗

July 15, 2024

Undervalued Nasdaq 100 stocks may not be as rare as hen's teeth but not quite so plentiful amid a raging bull market.

Via InvestorPlace

FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗

June 27, 2024

The FDA issued a Complete Response Letter for Daiichi Sankyo and Merck's BLA for patritumab deruxtecan targeting EGFR-mutated NSCLC due to third-party manufacturing facility inspection findings. The...

Via Benzinga

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

Via Benzinga

DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 ↗

April 30, 2024

Daiichi Sankyo Co just reported results for the third quarter of 2023.

Via InvestorPlace

Double Good News For AstraZeneca's Breast Cancer Drugs ↗

April 29, 2024

Results from AstraZeneca's Enhertu trial vs. chemotherapy in HR-positive, HER2-low metastatic breast cancer.

Via Benzinga

AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗

April 08, 2024

FDA approves Daiichi Sankyo's and AstraZeneca's Enhertu for unresectable or metastatic HER2+ solid tumors. Accelerated approval based on ORR and DOR. Boxed warnings for ILD/pneumonitis and embryo-fetal...

Via Benzinga

What's Going On With Pfizer Stock Today? ↗

January 25, 2024

Pfizer to announce Q4 2023 earnings on 30th Jan. Analysts project EPS loss of $(0.22) and $14.25B in revenues.

Via Benzinga

Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today ↗

January 03, 2024

Esperion Therapeutics, Inc. (NASDAQ: ESPR) shares are trading lower on Wednesday after the company announced a $125 million amendment to the collaboration with Japanese pharma company Daiichi Sankyo...

Via Benzinga

Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider ↗

December 20, 2023

Japanese stocks are gaining favor among I-banks and sport attractive valuations; here are 3 stocks with low P/B that have outperformed and could generate shareholder wealth.

Via Benzinga

Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? ↗

October 31, 2023

In due time, its new partnership with Daiichi Sankyo could be massive.

Via The Motley Fool

Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗

September 22, 2023

AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC:

Via Benzinga

AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials ↗

September 11, 2023

Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) and AstraZeneca plc (NASDAQ: AZN) released initial results from the TROPION-Lung04 phase 1b tria

Via Benzinga

FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt ↗

July 21, 2023

The FDA has approved Daiichi Sankyo's (OTC: DSNKY) Vanflyta (quizartinib) in

Via Benzinga

Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More ↗

July 04, 2023

World's Largest Psychedelics Conference Boasts 12K Attendees

Via Benzinga

AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial ↗

July 03, 2023

AstraZeneca Plc (NASDAQ: AZN) reported high-level results from the TROPION-Lung01 Phase 3 trial of datopotamab deruxtecan (Dato-DXd) in patients with locally advanced or metastatic non-small cell lung...

Via Benzinga

Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines ↗

June 27, 2023

Australia biotech startup Psylo has inked a sponsored research agreement with global Japanese pharmaceutical company Daiichi Sankyo (OTCMKTS: DSNKY) toward advancing antidepressant psychiatric...

Via Benzinga

< Previous 1 2 3 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.